| 1) Core items |
| Test code |
Test name |
Clinical description |
| E569 |
B-Type Natriuretic Peptide (BNP) |
Reflects ventricular stress and heart failure status |
| W395 |
Cardiovascular disease predictive test (sdLDL cholesterol+lipid panel) |
Assessment of inflammatory status and prognosis in cardiovascular diseases |
| C120 |
Cholesterol, High-Density Lipoprotein (HDL) |
Cardioprotective marker |
| C121 |
Cholesterol, Low-Density Lipoprotein (LDL) |
Prediction of atherosclerotic risk |
| C119 |
Cholesterol, Total |
Evaluation of dyslipidemia and cardiovascular risk |
| C109 |
CK-MB (Quantitative) |
Elevated in myocardial injury and used for the diagnosis of myocardial infarction |
| Z977 |
C-Reactive Protein (CRP, High sensitivity) |
|
| C108 |
Creatine Kinase (CK) |
Assessment of skeletal and cardiac muscle injury |
| S421 |
Homocysteine |
High levels are associated with increased risk of atherosclerosis and thrombosis |
| S446 |
Myoglobin [S] |
Elevated in myocardial and skeletal muscle injury; used for early screening of myocardial infarction |
| S805 |
NT-Pro BNP |
Diagnosis and severity assessment of heart failure |
| C122 |
Triglycerides (TG) |
Assessment of lipid metabolism based on serum triglyceride levels |
| E301 |
Troponin I |
Essential marker of myocardial injury for early diagnosis of acute myocardial infarction |
| S757 |
Troponin T (High Sensitive) |
Used for early detection of myocardial injury and risk assessment |
| 2) Optional items |
| Test code |
Test name |
Clinical description |
| S505 |
Apolipoprotein A1 |
Indicator reflecting HDL functionality and cardioprotective effects |
| S504 |
Apolipoprotein B |
Assessment of atherosclerotic risk associated with LDL levels |
| H127 |
aPTT |
Assessment of the intrinsic coagulation pathway and screening for bleeding disorders |
| N129 |
Interleukin-6 [ECLIA] |
Used for assessment of inflammation and progression of heart failure |
| C673 |
Lipoprotein (a) |
Assessment of genetic cardiovascular risk factors and prediction of early-onset vascular disease |
| C163 |
Phospholipids [S] |
Evaluation of thrombotic risk disorders, including antiphospholipid syndrome |
| H130 |
PT |
Evaluation of coagulation abnormalities or monitoring of anticoagulant therapy |
| 3) Supplementary items |
| Test code |
Test name |
Clinical description |
| H421 |
Antithrombin Ⅲ Activity (AT Ⅲ) |
Evaluation of anticoagulant protein deficiency and thrombotic risk |
| N041 |
MTHFR A1298C [Real-time PCR] |
Genetic variants related to hyperhomocysteinemia |
| M672 |
MTHFR C677T [Real-time PCR] |
Genetic variants associated with cardiovascular disease and thrombotic risk |
| L526/N685 |
Whole blood viscosity test |
Adjunctive assessment for prevention of cardiovascular and cerebrovascular diseases, and evaluation of hyperviscosity syndrome |
